Apnea, Obstructive Sleep, SARS CoV 2 Infection
Conditions
Keywords
Obstructive Sleep Apnea, Innate immunity, SARS-CoV-2
Brief summary
Sleep is an important modulator of the immune response, whereby sleep disturbances (ie, poor sleep quality, insufficient sleep and/or primary sleep disorder, obstructive sleep apnea (OSA)) contribute to inflammatory disease risk and dysregulation of immune response in front of infectious agents. The objective of this study is to evaluate the impact of undiagnosed and non-treated sleep disorders on innate immunity in a cohort of COVID-19 patients and the role of trained immunity induced by influenza vaccination in the innate immune response.
Detailed description
Sleep and immune system have reciprocal relationship. Sleep has a restorative role on immune system, influencing innate and adaptive immunity and sleep disorders can decrease immune response. Healthy innate immunity is crucial into regulation of the response against SARS-CoV-2. The hypothesis of the study is that the innate immunity response is blunted by sleep disorders and, this mitigated immune response, could influence on COVID-19 severity. Impaired immune response in patients with sleep disorders could be ameliorated inducing trained immunity by influenza vaccine.
Interventions
BIOLOGICALInfluvac Tetra
All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
Sponsors
Parc Taulí Hospital Universitari
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants over 18 years old with diagnosis of COVID-19 during first year of coronavirus pandemic in March-June 2021.
Exclusion criteria
* \>70 years and \<18 years * Recent COVID-19 (\<6 months) * Other infection (\<3 months) * Obstructive sleep apnea in treatment with CPAP prior to COVID infection. * Immunosuppressed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunological study: cytokines. | To evaluate immune response blood samples will be taken at the time influenza vaccine is given, 7 and 30 days later. | To measure in blood: IL-1 beta, IL-6, IL-8, IL-10, TNF-alfa, IFN-alfa, IFN-gamma, GM-CSF. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Innate cells: monocytes, classical dendritic cells and Natural Killer cells. | To evaluate immune response blood samples will be taken at the time influenza vaccine is given, 7 and 30 days later. | To measure: monocytes (CD45, CD14, CD16, HLA-DR), classical dendritic cells (CD45, CD1c, CD141, CD11c, CD86) and NK cells (CD45, CD56, CD16, Pan-KIR2D, NKG2D |
| Epigenetic modification. | To evaluate immune response blood samples will be taken at the time influenza vaccine is given, 7 and 30 days later. | To measure: H3K4me3, H3K4me1 and H3K27Ac |
| Diagnostic of obstructive sleep apnea in selected cohort | It is an overnight study that will last for one night. | Night home sleep study with WatchPAT® 300. |
Countries
Spain
Contacts
Primary ContactAndrea F Grau, Medicine
Outcome results
None listed